generic adj. 1.【生物学】属的,类的。 2.一般的,普通的 (opp. specific). 3.(商品)未注册的;不受商标注册保护的。 4.【语法】全称的,总称的。 a generic name 属名。 the generic singular [plural] 全称单数[复数]。 the generic person 全称人称〔one, you 等〕。 n. = a generic drug 未注册的药品(如 aspirin)。 n. -ness
Breakingnews alerts generic versions of certain biologics have been allowed ineurope for the last four years , but approval came only aftermanufacturers conducted rigorous human clinical trials 最新消息提醒说某些生物药品在过去的四年里被允许,但只有制药企业实施了严格的人类临床试验才能得到批准。
Now , even the local pharmaceutical companies , traditionally manufacturers of generic versions of brand - name drugs , are embracing innovation - based business models and seeking patent protection for their inventions 现在,即便是传统上药物品牌非专利的地方制药公司,也走上创新型企业发展模式,为其发明创造寻求专利保护
Now , even the local pharmaceutical companies , traditionally manufacturers of generic versions of brand - name drugs , are embracing innovation - based business models and seeking patent protection for their inventions 现在,即使是当地的制药公司或着是传统品牌的制造公司都在使用新创新的经营模式并为自己的产品寻求专利保护
Genericsthat are chemical equivalents to conventional drugs save americans atleast $ 10 billion per year . the food and drug administration , however , lacks the legal ability to approve generic versions of biologics 仿制药为传统药物的化学等价物,它每年至少为美国人节省100亿美元。而食品和药物管理局缺乏相关的法律权能去批准生物药品的仿制。
Now , even the local pharmaceutical companies , traditionally manufacturers of generic versions of brand - name drugs , are embracing innovation - based business models and seeking patent protection for their inventions 现在,即使是当地的医药公司,还是品牌的转基因药物的传统生产厂家都正极力迎合以创新为本的商业模式,并为自己的新发明寻求专利保护
In simple terms , the way that it works is that a branded company that is selling its product in the us grants a generic company the right to market a generic version of its product before any competitors launch a generic 简单说来它(授权的非专利药)就是,在任何竞争者上市非专利药之前,在美国销售品牌药的公司授权一个非专利药公司销售其产品的非专利药。
This week it confirmed it approved a cheap , copycat version of a blockbuster heart disease medication - the first time a developing country has torn up the international patent for treatments like this - and a generic version of an aids drug 这周他们宣告一鸣惊人信息,说成功研发出了一种廉价的治疗心脏疾病的仿制药物- -这是发展中国家第一次撕碎国际专利特权- -并生产出爱滋病普通仿制药。
Canada grants patent waiver for rwanda aids drug reuters newmedia - october 5 , 2007 canada has authorised a company to make a generic version of a patented aids therapy drug for export to rwanda , in the first case of a patent waiver under world trade organisation ( wto ) rules 加拿大:加拿大签署协议,放弃卢旺达艾滋药品专利路透社2007年10月5日根据世贸组织条例,加拿大已经授权一家公司生产出口到卢旺达的专利注册的艾滋药品。
The dilemma that regulators face is whether to require generics firms to conduct such large , lengthy and expensive trials ? thus effectively raising the price of biogenerics ? or whether to make informed guesses about whether subtle differences in the generic version will harm patients 主管单位面临的两难是:到底要不要让学名药的制造商进行这麽庞大、漫长又昂贵的实验,因而提高生技学名药的售价;还是要让知情者自行猜测学名药的微小差异是否会对病人造成伤害。
This price difference is largely due to the lack of generic competition in the second - line market : there are presently no generic versions of tfv and only one generic version of lpv r . there are generic versions of enterocoated ddi , but they are not available in south africa and many other countries . the manufacturer bristol - myers squibb has refused to include enterocoated ddi in its differential pricing policy , making the drug much more expensive 这个价格差异,是因为第二线药物?场缺乏仿制药的竞争:泰诺福韦目前尚未有仿制药,洛匹那韦利托那韦只有一种仿制药,地丹诺辛的肠溶剂型则在南非及许多国家找不到仿制药,加上原创药厂拒绝把地丹诺辛的肠溶剂型纳入其差别定价的政策之内,令该药价格更高。